Lazcluze (lazertinib) is a third-generation, brain-penetrant EGFR tyrosine kinase inhibitor (TKI) approved for first-line treatment of EGFR-mutated non–small cell lung
Lazertinib is used for the treatment of non-small cell lung cancer (NSCLC) in patients who have tumors with specific mutations in the epidermal growth factor receptor (EGFR) gene. It is mainly used in cases where the cancer has become resistant to earlier EGFR-targeted therapies.
How much does Lazertinib cost?
The cost of Lazertinib can vary depending on the country, dosage, insurance coverage, and distributor.
What is the difference between Lazertinib and Osimertinib?
Both Lazertinib and Osimertinib are third-generation EGFR tyrosine kinase inhibitors (TKIs) designed to treat EGFR-mutated NSCLC, particularly the T790M mutation. The key differences lie in their molecular structure, side effect profiles, resistance patterns, and pharmacokinetics.
Is Lazertinib FDA-approved?
As of now, Lazertinib has not yet received FDA approval in the United States. However, it has been approved in South Korea and is currently under evaluation in multiple international clinical trials, including combinations with other therapies, such as amivantamab.
What is the survival rate for Lazertinib?
Survival rates can vary depending on the stage of the disease and the combination therapies used. In clinical trials, Lazertinib has shown promising progression-free survival (PFS) and overall survival (OS) in EGFR-mutated NSCLC.
What is another name for Lazertinib?
Lazertinib is also known by its development code YH25448. Its proposed trade name is Leclaza®, which is used in markets like South Korea where it is approved.
Is Lazertinib a pill?
Yes, Lazertinib is administered orally in tablet form, making it convenient for patients to take at home. The typical dose used in clinical settings is 240 mg once daily; however, the dosage may vary depending on the patient’s condition.
How does Lazertinib work?
Lazertinib works by selectively inhibiting mutant forms of the EGFR, including the T790M mutation that often causes resistance to first- and second-generation EGFR inhibitors. It blocks the EGFR signaling pathway, which helps stop cancer cell growth and induces cell death in tumors with EGFR mutations.
When was Lazertinib approved?
Lazertinib was approved in South Korea in January 2021 under the brand name Leclaza® for the treatment of EGFR T790M-positive NSCLC. It is still undergoing regulatory review and clinical evaluation in other countries, including the U.S. and Europe.
What generation is Lazertinib?
Lazertinib is classified as a third-generation EGFR tyrosine kinase inhibitor (TKI). This generation is designed to target resistant mutations, such as T790M, while minimizing activity against wild-type EGFR to reduce side effects.
